Brokers Offer Predictions for FibroGen FY2024 Earnings

FibroGen, Inc. (NASDAQ:FGEN) – Equities researchers at HC Wainwright issued their FY2024 earnings per share estimates for shares of FibroGen in a research report issued on Tuesday, December 17th. HC Wainwright analyst M. Keller anticipates that the biopharmaceutical company will post earnings per share of ($0.74) for the year. HC Wainwright currently has a “Strong-Buy” rating on the stock. The consensus estimate for FibroGen’s current full-year earnings is ($0.86) per share. HC Wainwright also issued estimates for FibroGen’s Q4 2024 earnings at ($0.08) EPS and FY2025 earnings at ($0.53) EPS.

FibroGen (NASDAQ:FGEN) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.21. The firm had revenue of $46.33 million during the quarter, compared to the consensus estimate of $34.00 million. During the same period last year, the business earned ($0.52) earnings per share.

Several other brokerages have also commented on FGEN. StockNews.com started coverage on FibroGen in a research note on Monday. They issued a “hold” rating on the stock. William Blair reiterated a “market perform” rating on shares of FibroGen in a research report on Wednesday, November 13th.

FibroGen Stock Performance

Shares of FibroGen stock opened at $0.35 on Thursday. The firm has a market cap of $35.64 million, a P/E ratio of -0.29 and a beta of 0.82. The firm’s 50-day simple moving average is $0.35 and its 200-day simple moving average is $0.57. FibroGen has a twelve month low of $0.18 and a twelve month high of $2.93.

Institutional Trading of FibroGen

Hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC grew its holdings in FibroGen by 3.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock worth $433,000 after acquiring an additional 32,884 shares during the last quarter. Sei Investments Co. lifted its position in shares of FibroGen by 38.4% during the second quarter. Sei Investments Co. now owns 149,342 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 41,442 shares in the last quarter. Point72 DIFC Ltd grew its stake in shares of FibroGen by 734.2% during the second quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 45,990 shares during the last quarter. Doheny Asset Management CA acquired a new stake in shares of FibroGen in the second quarter valued at approximately $48,000. Finally, FMR LLC increased its holdings in shares of FibroGen by 21.8% in the third quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock valued at $153,000 after purchasing an additional 68,569 shares in the last quarter. 72.71% of the stock is currently owned by institutional investors and hedge funds.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.